Home LiteratureArticle Details
PMID: 16627760 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

Blood ·Vol. 108 ·No. 3 ·2006-08-01 ·Pages 1050-7

Flotho C, Coustan-Smith E, Pei D, Iwamoto S, Song G, Cheng C, Pui CH, Downing JR, Campana D

Abstract

In childhood acute lymphoblastic leukemia (ALL), early response to treatment is a powerful prognostic indicator. To identify genes associated with this response, we analyzed gene expression of diagnostic lymphoblasts from 189 children with ALL and compared the findings with minimal residual disease (MRD) levels on days 19 and 46 of remission induction treatment. After excluding genes associated with genetic subgroups, we identified 17 genes that were significantly associated with MRD. The caspase 8-associated protein 2 (CASP8AP2) gene was studied further because of its reported role in apoptosis and glucocorticoid signaling. In a separate cohort of 99 patients not included in the comparison of gene expression profiles and MRD, low levels of CASP8AP2 expression predicted a lower event-free survival (P = .02) and a higher rate of leukemia relapse (P = .01) and were an independent predictor of outcome. High levels of CASP8AP2 expression were associated with a greater propensity of leukemic lymphoblasts to undergo apoptosis. We conclude that measurement of CASP8AP2 expression at diagnosis offers a means to identify patients whose leukemic cells are highly susceptible to chemotherapy. Therefore, this gene is a strong candidate for inclusion in gene expression arrays specifically designed for leukemia diagnosis.

MeSH Terms
Adolescent Apoptosis Apoptosis Regulatory Proteins/genetics Calcium-Binding Proteins/genetics Child Child, Preschool Disease-Free Survival Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Infant Male Neoplasm, Residual/genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis,genetics Predictive Value of Tests Prognosis Recurrence Remission Induction Treatment Outcome
Chemicals
Apoptosis Regulatory Proteins CASP8AP2 protein, human Calcium-Binding Proteins
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Flotho Christian
Department of Pathology, St Jude Children's Research Hospital, 332 N Lauderdale, Memphis, TN 38105, USA.
Coustan-Smith Elaine
Pei Deqing
Iwamoto Shotaro
Song Guangchun
Cheng Cheng
Pui Ching-Hon
Downing James R
Campana Dario
References (44)
44 references, click to expand
  1. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements.
    Leukemia. 2003 Apr;17(4):700-6 PMID: 12682627
  2. Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment.
    Curr Opin Hematol. 2003 Jul;10(4):290-6 PMID: 12799535
  3. Prognostic importance of chromosome number in 136 untreated children with acute lymphoblastic leukemia.
    Blood. 1982 Oct;60(4):864-71 PMID: 6956375
  4. Stroma-supported culture in childhood B-lineage acute lymphoblastic leukemia cells predicts treatment outcome.
    J Clin Invest. 1996 Feb 1;97(3):755-60 PMID: 8609232
  5. The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis.
    Nature. 1999 Apr 29;398(6730):777-85 PMID: 10235259
  6. Determination of minimal residual disease in leukaemia patients.
    Br J Haematol. 2003 Jun;121(6):823-38 PMID: 12786792
  7. Analysis of matched mRNA measurements from two different microarray technologies.
    Bioinformatics. 2002 Mar;18(3):405-12 PMID: 11934739
  8. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia.
    Best Pract Res Clin Haematol. 2002 Mar;15(1):1-19 PMID: 11987913
  9. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.
    Leukemia. 2004 May;18(5):934-8 PMID: 15029212
  10. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.
    Blood. 2002 Oct 1;100(7):2399-402 PMID: 12239148
  11. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.
    Lancet. 1998 Feb 21;351(9102):550-4 PMID: 9492773
  12. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.
    Blood. 2002 Jul 1;100(1):52-8 PMID: 12070008
  13. Cell cycle dependent regulation of the protein kinase TTK.
    Oncogene. 1994 Jan;9(1):89-96 PMID: 8302607
  14. A multiplex RT-PCR assay for the detection of chimeric transcripts encoded by the risk-stratifying translocations of pediatric acute lymphoblastic leukemia.
    Leukemia. 1998 Dec;12(12):1994-2005 PMID: 9844930
  15. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
    Blood. 2000 Oct 15;96(8):2691-6 PMID: 11023499
  16. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study.
    J Clin Oncol. 1992 Apr;10(4):606-13 PMID: 1548523
  17. Immunophenotyping of leukemia.
    J Immunol Methods. 2000 Sep 21;243(1-2):59-75 PMID: 10986407
  18. DAXX, FLASH, and FAF-1 modulate mineralocorticoid and glucocorticoid receptor-mediated transcription in hippocampal cells--toward a basis for the opposite actions elicited by two nuclear receptors?
    Mol Pharmacol. 2004 Mar;65(3):761-9 PMID: 14978255
  19. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling.
    Blood. 2003 Oct 15;102(8):2951-9 PMID: 12730115
  20. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia.
    Blood. 2006 Jan 15;107(2):769-76 PMID: 16189266
  21. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    N Engl J Med. 1998 Aug 27;339(9):591-8 PMID: 9718378
  22. Tumor necrosis factor alpha receptor- and Fas-associated FLASH inhibit transcriptional activity of the glucocorticoid receptor by binding to and interfering with its interaction with p160 type nuclear receptor coactivators.
    J Biol Chem. 2003 Jan 31;278(5):3023-9 PMID: 12477726
  23. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
    Cancer Cell. 2002 Mar;1(2):133-43 PMID: 12086872
  24. Interleukin-4 variant (BAY 36-1677) selectively induces apoptosis in acute lymphoblastic leukemia cells.
    Blood. 2001 Feb 1;97(3):752-8 PMID: 11157494
  25. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.
    N Engl J Med. 2004 Aug 5;351(6):533-42 PMID: 15295046
  26. Minimal residual disease in leukaemia patients.
    Lancet Oncol. 2001 Jul;2(7):409-17 PMID: 11905735
  27. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.
    Blood. 2004 Nov 1;104(9):2690-6 PMID: 15251979
  28. Childhood acute lymphoblastic leukaemia--current status and future perspectives.
    Lancet Oncol. 2001 Oct;2(10):597-607 PMID: 11902549
  29. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival.
    Blood. 2004 Apr 1;103(7):2771-8 PMID: 14684422
  30. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
    Blood. 2005 Jan 15;105(2):821-6 PMID: 15388585
  31. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
    Blood. 2000 Feb 1;95(3):790-4 PMID: 10648387
  32. Statistical significance threshold criteria for analysis of microarray gene expression data.
    Stat Appl Genet Mol Biol. 2004;3:Article36 PMID: 16646816
  33. Role of FLASH in caspase-8-mediated activation of NF-kappaB: dominant-negative function of FLASH mutant in NF-kappaB signaling pathway.
    Oncogene. 2005 Jan 20;24(4):688-96 PMID: 15592525
  34. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.
    Leukemia. 2004 Mar;18(3):499-504 PMID: 14981525
  35. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia.
    Blood. 1992 May 1;79(9):2370-7 PMID: 1373973
  36. Correlation of protein expression and gene expression in acute leukemia.
    Cytometry B Clin Cytom. 2003 Sep;55(1):29-36 PMID: 12949957
  37. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
    Blood. 2005 Sep 1;106(5):1778-85 PMID: 15905191
  38. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes: a distinct biological entity with a marked propensity to undergo apoptosis.
    Blood. 1999 Jan 1;93(1):315-20 PMID: 9864176
  39. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    Lancet. 1998 Nov 28;352(9142):1731-8 PMID: 9848348
  40. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells.
    Nat Genet. 2003 May;34(1):85-90 PMID: 12704389
  41. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
    Cancer Cell. 2005 Apr;7(4):375-86 PMID: 15837626
  42. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.
    Br J Haematol. 1997 Mar;96(3):601-10 PMID: 9054669
  43. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia.
    J Clin Oncol. 2005 Nov 1;23(31):7936-41 PMID: 16258093
  44. Acute lymphoblastic leukemia.
    N Engl J Med. 2004 Apr 8;350(15):1535-48 PMID: 15071128
Article Info
Journal
Blood
Abbr.
Blood
ISSN
0006-4971
Published
2006-08-01
Epub
2006-00-20
Pages
1050-7
Language
English
Region
United States
NLM ID
7603509
PMCID
PMC1895863
Subset
IM
Grants
NCI NIH HHS · CA21765 · United States
NCI NIH HHS · CA60419 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]